Prudentia Sciences

The JP Morgan Healthcare Conference 2025 marked an exciting milestone as Prudentia Sciences made its debut. We are deeply grateful for the engagement and interest from biopharma leaders, visionary investors, and insightful bankers—all united by a shared passion for shaping the future of dealmaking. With 2025 poised to be a transformative year for asset evaluations, M&A, and licensing, our conversations at JPM highlighted the growing significance of real-time decision-making, data-driven insights, and strategic capital allocation in driving drug development success. A heartfelt thank you to everyone who took the time to connect with us at the event. Your ideas and feedback inspire us to push boundaries and continue innovating to advance our industry. If we didn’t have the opportunity to connect during the conference, we’d love to hear from you! Let’s keep the conversation going and explore how we can collaborate to shape the future of drug development together. #JPM2025 #Biopharma #Dealmaking #AI #DrugDevelopment #PrudentiaSciences

Exclusive: Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent drugmakers from missing out on their next big deal. Prudentia Sciences raised a $7 million seed round in the fall led by GV (Google Ventures), the venture arm of Alphabet, CEO Sadiqa Mahmood told me. Iaso Ventures and Virtue are also investors. My latest at Endpoints News:

Exciting News: Prudentia Sciences Launches with $7M in Funding to Revolutionize Life Sciences Dealmaking! We are thrilled to announce the public launch of Prudentia Sciences, a cutting-edge AI-powered technology platform designed to accelerate drug pipelines, optimize capital allocation, and transform how biopharma companies and investors approach asset diligence and valuation. With $7 million in seed funding led by GV (Google Ventures), with participation from Iaso Ventures and Virtue, we are poised to empower decision-makers across the life sciences sector to make faster, more informed, and data-driven dealmaking. Prudentia was purpose-built to fill a key market gap: Prudentia's AI-driven software platform helps biopharma and investors accelerate drug pipelines and maximize return on investment. Big shout out and congratulations to the Prudentia team! We also want to share a deep appreciation for our advisors, supporters and investors, particularly Wasim Malik, Anthony Philippakis, Crystal Huang, Raymond Sanchez, M.D., Travis May, Sean Doolan, Emre Karatas, Stuart Chaffee, Matthew Leoni, MD, MBA, Josef von Rickenbach, Mark Currie, Jennifer Byrne, Dan Burton. ???? #LifeSciences #AI #Biopharma #Investment #Dealmaking #Startups #PrudentiaSciences #Funding ???Check out the full announcement here:

Prudentia is #hiring a new Senior Data Scientist!